Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the formulary and RAG list have been updated to add Cyclogest pessaries as an option for management of threatened miscarriage.
The full formulary is available on the formulary page.
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2023 virtual CRG meeting. Actions in this consultation include:
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until midday on Tuesday 2nd May 2023.
Following approval by GM ICB exec, the following decisions have been approved and published:
The formulary has also been updated to reflect relevant safety alerts. For full details please see the formulary change log, which is available on the formulary page.
For more information on these and other decisions, please see GMMMG decision summaries.
Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the following documents have been approved and published.
The GMMMG Inappropriate Polypharmacy Review and Treatment Optimisation: Resource Pack has been reviewed and updated. The updated resource pack is available on the Clinical Guidelines and Pathways page.
Terms of reference for the Workforce subgroup have also been approved, and are available on the Membership and Terms of Reference page.
The formulary and RAG list have been updated to remove fostamatinib from the RAG list and assign a RED RAG status, and to reflect updated NICE guidelines and MHRA advice. See formulary change log for more details.
Outstanding decisions expected to have a financial impact for the ICS are pending financial approval from by GM Directors of Finance, and will be published once approved. These include:
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the February 2023 CRG meeting.
Actions in this consultation include:
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 30th March 2023.
The lipid management pathway for secondary prevention of cardiovascular disease has been updated. Changes include:
The updated pathway is available on the clinical guidance and pathways page, along with links to other lipid management resources.
Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, two new GMMMG guidelines have been published;
Both guidelines are available on the clinical guidance and pathways page.
The formulary and RAG list have been updated to reflect the recommendations in these guidelines. For details of the updates, see the GM formulary change log, available on the formulary page.
The Terms of Reference for GMMMG and its subgroups have also been approved, and are available here. These include:
Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the following decisions have been approved and published:
The formulary has also been updated to reflect relevant NICE guidelines and safety alerts. For full details please see the formulary change log, which is available on the formulary page.
For more information on these and other decisions, please see GMMMG decision summaries.
Following approval by CRG and GMMMG, and the first meeting of the Greater Manchester ICS Clinical Effectiveness and Governance Committee on Thursday 22nd September, a shared care protocol for melatonin in children adolescents has been updated.
All of the currently active shared care protocols in Greater Manchester are available on the shared care page.
Following approval by CRG, GMMMG, and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, the following decisions have been approved and published:
The formulary has also been updated to reflect relevant NICE guidelines and safety alerts. For full details please see the formulary change log, which is available on the formulary page.
For more information on these and other decisions, please see GMMMG decision summaries.